16 March 2020 – Insightec Targets $150m Series F

The Big Ones

Insightec is targeting up to $150m in a series F round valuing it at $1.3bn post-money, and has already received a $100m commitment from Koch Disruptive Technologies to lead the round. The company is developing a system that will use ultrasound to conduct brain surgery without making an incision, and KDT also led its last round, a $150m series E in 2017.

Investment firm LSP has raised $600m for its LSP 6 fund, which it claims is the largest life sciences venture fund in Europe’s history. Limited partners for the fund, which significantly surpassed its $450m target, include pharmaceutical firms Bristol Myers Squibb and Otsuka Pharmaceutical. Netherlands-based LSP now has a total of $1.1bn at its disposal across three funds.

WeDoctor, the operator of a medical appointment booking platform, is reportedly interviewing investment banks for roles in a Hong Kong initial public offering potentially sized at up to $1bn. The company’s investors include Tencent, Fosun, Shandong Tyan Home, NWS Holdings and AIA, the latter two having co-led its last round in mid-2018, when it raised $500m at a $5.5bn valuation. The IPO is reportedly expected to value it at up to $10bn.

And in crossover news, Passage Bio, a US-based genetic medicines developer commercialising University of Pennsylvania research, has increased its initial public offering to more than $248m after underwriters exercised their over-allotment option in full. Underwriters purchased 1.8 million additional shares at the initial public offering price of $18, thereby injecting $32.4m into the company.

Deals

Kymera Therapeutics has closed a $102m series C round that will fund the progress of its immunotherapy pipeline, with cancer, autoinflammatory and autoimmune diseases in its eyeline. Although none of them were named as participants in the round, Kymera has a raft of earlier investors from the pharmaceutical industry including MRL Ventures, Sanofi Ventures, Lilly Ventures, Amgen Ventures and Vertex Pharmaceuticals.

Elsewhere in China but in a completely different sector entirely, agricultural product distributor Wangjiahuan has closed an $87m series B round led by local services portal Meituan Dianping. The round also featured GLP’s $1.6bn Hidden Hill fund, which had supplied $58.5m in series A funding for Wangjiahuan roughly 18 months ago.

The hospitality sector looks like it’s facing an uncertain time right now, but hospitality management software provider Cloudbeds has raised $82m in funding from participants including human resources firm Recruit. The round was led by Viking Global Investors and it followed a reported $20m in earlier funding, with existing investors PeakSpan Capital and Cultivation Capital returning for the latest round.

Bristol-Meyers Squibb has contributed to a series B round for Silverback Therapeutics that has closed at $78.5m. The biologic drug developer had previously raised $47.5m in a Celgene-backed series A round, and the latest cash will be used to progress its lead antibody into clinical trials in cancer.

ShopBack, the operator of an online consumer loyalty and rewards platform, has boosted a funding round that already included Rakuten Capital to $75m. Temasek led the full round, which the company said increased its overall funding to $113m. EV Growth, whose co-founders include Yahoo Japan and Sinar Mas, also took part, ShopBack’s earlier backers including InTouch, SoftBank Ventures Asia and Singtel Innov8.

Health benefits provider Lyra Health has also raised $75m, in a series C round that included Providence Health and Services ‘ corporate VC unit, Providence Ventures, that lifted its overall funding to at least $158m. The round was led by venture capital firm IVP and Castlight Health is among the company’s earlier investors.

Elsewhere in life sciences, Harbour BioMed has closed a $75m series B-plus round that included SK Holdings, Legend Capital and Zhejiang University Future Capital. Harbour is working on antibody-based therapies for cancer and inflammatory diseases but has now added a Covid-19 candidate to its pipeline. If it hits with that, expect its valuation to skyrocket. It traces its roots back to the Erasmus MC hospital.

Pager, the developer of a medical communication app, has secured $33m in equity and debt financing from investors including health insurance provider Horizon Blue Cross Blue Shield of New Jersey. The company’s earlier backers include Horizon Healthcare Services and Grupo Sura, and the latest funding will support geographical growth and product development.

Funds

Gas utility Enagás has also been busy fundraising and has put together a $170m fund in partnership with investment bank Alantra that will provide capital for renewable energy technology developers. The corporate is providing approximately $22.7m as a first commitment to Clima Energy Transition Fund and will also offer its expertise to portfolio companies.

Corporate venturing vehicle Strive rebranded from Gree Ventures last year and put down a target of more than $130m for its third fund – essentially double the amount it raised for the predecessor. In the end, Strive has closed the fund at just over $100m. It said the main priority was to reach $100m and that its central goal is to concentrate on its portfolio companies rather than fundraising.

Exits

Small molecule drug developer Zentalis is one of several life sciences companies to have filed for IPOs in recent days (see Ayala below), and it is targeting $100m in a Nasdaq offering. The decision comes after $162m in funding and will give Pharmaron the chance to exit. Let’s just hope the recent downturn in the public markets proves to be temporary rather than something longer lasting.

It maybe be hard going in the public markets right now but Imara has nevertheless gone public, raising $75.2m in an IPO that involved it floating at the bottom of its range, despite marginally increasing the number of shares in the offering. Imara is developing therapies to combat blood disorders and its shareholders include Lundbeckfond Invest and Pfizer Ventures, which hold a combined 15% of the company post-IPO.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

02 March 2020 – Grab Raises $856m from Mitsubishi UFJ Financial Group

The Big Ones

There may be fewer rounds being closed but ride hailing continues to be a money magnet, with Grab raising $856m from Mitsubishi UFJ Financial Group – which invested $706m – and TIS, both investing through newly struck partnership deals that will centre on the joint development of payment and financial services technology. There may be a bigger deal in the pipeline too, with reports stating Grab has been in talks with key rival Gojek over a merger that could value the combined company at $23bn.

Southeast Asia has been one of the fastest growing areas of the world for corporate VC funds. One of the relatively early participants was state-owned telecommunications operator Telkom Indonesia, which launched unit MDI Ventures in 2016 with $100m, and which has rapidly expanded since. MDI Ventures is targeting $300m to $500m for its second fund, according to comments made by a government minister this week, and that amount would represent a big step forward in terms of capital. Probably justifiably, given the recent emergence of unicorns like Grab, Gojek and Tokopedia.

CapitalG, the growth equity subsidiary of Alphabet is in line for a healthy exit, as media reports suggest tax software provider Intuit is set to buy credit management platform Credit Karma in a $7bn cash-and-stock deal. CapitalG first invested in Credit Karma at a valuation of less than $1bn in 2014, and the company was valued at $3.5bn in its last funding round the following year.

And in crossover news (of which there was actually a lot last week and we’ll get to more of them in a minute), we have another exit. University of Pennsylvania-linked Passage Bio went public on Friday in a $216m IPO in which it is floating at the top of its range ($18 a pop), after increasing the number of shares by more than 60% (from 7.4 million to 12 million shares). The genetic medicine developer only officially launched a year ago (though it was incorporated in 2017) but had pulled in $226m across two rounds, from investors including corporate vehicles Access Biotechnology and Lilly Asia Ventures. It’s also allocated 1.8 million shares to a greenshoe option (also up from 1.5 million) and if stock goes the way everyone wants it to, it likely won’t be too long before underwriters jump on that chance.

Deals

One of the more interesting corporate investor/portfolio company combinations in recent times is the tendency for carmakers to invest nine-figure sums in autonomous driving software developers in order to get a foothold in an area of technology thought by many to be the future of the industry. The latest is Toyota, which has already backed several ride hailing companies and which just provided $400m for robotaxi system developer Pony.ai as part of a $462m round.

Graphcore, an artificial intelligence processor developer that traces its roots back to University of Bristol (it’s a spinout of Bristol spinout Xmos), has added $150m to a series D round that now stands at $350m, valuing the company at $1.95bn. The $200m first tranche included BMW i Ventures, Robert Bosch Venture Capital, Dell Technologies Capital, Microsoft and Samsung, though none were explicitly identified as being among the existing backers that joined Baillie Gifford, M&G Investments, Mayfair Equity Partners and Merian Chrysalis in the second close.

GV and Intel Capital have both contributed to a $250m series C round for SambaNova Systems, an AI computing platform developer co-founded by Stanford University faculty, that will fuel the enhancement of its technology. GV co-led SambaNova’s series A round while Intel Capital led its $150m series B last year, and the increasing ubiquity of AI combined with the move to more complex areas like edge computing mean we’re likely to see the company continue to move up the fundraising levels in the coming years.

SpaceX is gearing up for another funding round, having raised more than $1.2bn since December 2018 across three different rounds. No word on whether those rounds included existing investor Google, but the new round is reportedly set to be sized at about $250m at a valuation of roughly $36bn. Its overall funding so far stands at around $3.4bn.

Karius has developed a liquid biopsy test that draws blood in order to discover information on disease by crunching data on microbial cell-free DNA found in the samples. It has also secured $165m in a series B round led by SoftBank’s second Vision Fund, which seems to well and truly be up and running (albeit still only with cash from SoftBank itself).

Despite being around some 15 years and racking up 115 monthly active users, Roblox has kept a relatively low profile in the startup scene, though that may be changing with news of a $150m series G round featuring Tencent. The company has created an online platform that allows users to develop virtual worlds and MMO games that others can play, and is reportedly now valued at $4bn. It’s also launching a secondary offering for up to $350m of common and primary shares.

Another company focusing on creativity (of a sort) is Uncorq, developer of a no-code platform enabling users to create software applications without coding. It’s added $51m to a series D round now totalling $131m, and CapitalG, which co-led the first tranche in October, led the extension. The cash will be used for recruitment and expanding the company’s partnerships along with its live event schedule.

JD.id, the Indonesian spinoff of e-commerce group JD.com launched in 2015 with private equity firm Provident Capital, is also valued at more than $1bn, a source has told Indonesian tech news portal Daily Social. The company has yet to confirm the identity of any external investors but rumours suggest they could include another Indonesian unicorn, Gojek. To square the circle, both JD.com and Provident invested in a $1bn round for Gojek early last year.

Funds

Energy management and automation technology producer Schneider Electric has supplied $10m for Israel-based venture capital firm Grove Ventures’ $120m second fund. The oversubscribed fund, Grove II, was closed a week ago without the firm identifying any limited partners, though its described them as institutional and strategic investors as well as industry leaders.

US-based, real estate-focused venture capital firm Fifth Wall closed a $100m fund on Wednesday that includes several property developers as limited partners. Commercial real estate provider Cushman & Wakefield is an LP, as are real estate investment trusts Macerich, Acadia Realty Trust and Nuveen Real Estate, the latter a subsidiary of asset manager TIAA Investments.

Japan-based venture capital firm I-Nest Capital has closed its first fund at ¥6.6bn ($61m) having secured commitments from backers including corporates Power Solutions and NTT Docomo. IT services firm Power Solutions and mobile network operator NTT Docomo were joined by financial services firm Mizuho Bank and Fuji Startup Ventures, a corporate venturing vehicle for media company Fuji TV. The limited partners were filled out by Mizuho Securities Principal Investment, which represents investment bank Mizuho Securities, and the Japanese government’s Organization for Small & Medium Enterprises and Regional Innovation.

Exits

Salesforce has agreed to acquire CRM app developer Vlocity, a portfolio company of its Salesforce Ventures unit, in a $1.33bn all-cash deal. Vlocity had raised $163m from an investor base that also included Accenture and New York Life, and the transaction marks the fifth M&A exit for Salesforce Ventures this year, following Simplus, Evariant, Quid and LevelEleven.

Food delivery has been one of the better funded portions of the mobile commerce market, perhaps second only to ride hailing, and DoorDash’s investors look like they may be in for a lucrative exit. The company has confidentially filed for an IPO, three months after closing its series G round at $700m, at a $13bn valuation.

It isn’t a conventional M&A corporate exit but Takeda is buying coeliac disease drug developer PvP Biologics three years after paying $35m for an option to fully acquire the University of Washington spinout once it had advanced its lead product candidate to a certain stage. The size of the deal could eventually reach $330m if PvP reaches every development and regulatory milestone and, its drug will join Takeda’s own celiac disease candidate in the corporate’s product pipeline.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

10 February 2020 – Netskope Gains $340m in Round Led By Sequoia Capital Global Equities

The Big Ones

Sequoia Capital Global Equities has led a $340m round for cloud security platform developer Netskope at a valuation of near $3bn. Netskope has now raised $740m altogether from investors including Dell Technologies Capital. Given the propensity of cybersecurity companies to be acquired, the unit – which has already scored exits from Packet and Big Switch Technologies this year – must feel good about that increased valuation.

Lots of Japanese financial services firms are active in the country’s venture capital space but SBI Group is one of the most strategic, having also backed international fintech developers such as Ripple and CurrencyCloud. It also raised a mid-nine figure amount for an AI and blockchain fund last year, and is now targeting $920m for a new vehicle called the 4+5 Fund.

Cybersecurity continues to be one of the most reliable areas for M&A exits and the latest case is Emailage, an email security software provider that has agreed to an acquisition by LexisNexis Risk Solutions, reportedly for around $480m.

And in crossover news, another exit… Harvard University-founded genomic medicine developer Beam Therapeutics looks set for one of the most successful of recent months, floating at the top of its range in an upsized IPO that will net it $180m.

Deals

SoftBank Vision Fund has provided another $150m for Indian childcare product retailer FirstCry, following on from a similarly sized investment a year ago and doubling its series E round to $300m.

GV’s latest investment involved it leading a $100m round for Verana Health, the operator of a software platform that pools clinical and life sciences information from a range of databases. The Alphabet-owned unit had already led Verana’s last round, a $30m series C 18 months ago, and it forms part of what’s becoming an increasingly lucrative healthcare technology stable.

Moda Operandi, the operator of an e-commerce marketplace for luxury goods, has secured $100m in debt and equity financing, increasing its equity funding to $345m in the process. The company, whose earlier investors include Advance Publications and LVMH, is one of several e-commerce entities to target the high-end market.

JenaValve Technology is moving its transcatheter aortic valve replacement prosthesis towards full regulatory approval in the US and has raised $50m from investors including Legend Capital to fund that journey. Legend Capital also took part in the company’s last publicly disclosed round, a series C that closed at $99m nearly five years ago.

Sendoso, the operator of a platform that combines software and warehousing services to help businesses with their postal marketing, has received $40m in funding from investors including logistics real estate manager Prologis. The round was led by Oak HC/FT and it boosted the company’s overall funding to more than $54m.

Exits

Qorvo has agreed to acquire Decawave, an indoor positioning technology developer that had raised about $60m from investors including ST Electronics and LG, for a reported $400m in cash. The deal was announced alongside semiconductor technology producer Qorvo’s purchase of another company, for a total of $500m.

Schrödinger, which provides chemical simulation software enabling drug developers to more precisely analyse molecules, floated above its range to raise $202m. The GV and WuXi AppTec-backed company then saw its shares shoot up 68% on their first day of trading.

Cancer therapy developer Revolution Medicines has set the terms for its initial public offering and will raise $150m if it floats at the mid-point of its range, $160m if it floats at the top.

Passage Bio, a University of Pennsylvania-linked drug developer that – by a bizarre coincidence – has also raised $226m, has filed for its own IPO, setting a $125m target.

Casper Sleep on the other hand has had some of the worst pre-IPO publicity since, well, WeWork, with onlookers pointing to steady losses and what’s perceived as an (ahem) relatively sleepy corner of the consumer products sector. The Target-backed mattress and bedding brand raised a sliver over $100m, floating at the bottom of an already slashed price range at less than half the $1.1bn valuation at which it last raised funding. Ouch.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

09 September 2019 – Nikola Corporation Raises $250m

Deals

Sumitomo Dainippon Pharma is acquiring a stake in medical company builder Roivant that will be at least 10%, as part of a $3bn deal that will involve it also taking Roivant’s stake in five subsidiaries.

Despite being responsible for unicorns DraftKings and FanDuel, daily fantasy sports has run into a string of regulatory issues in the US. India-based Dream11 seems to be faring better, suprassing $1bn of transactions in its last year of operations, and it is reportedly in talks with investors including SoftBank Vision Fund and Naspers Ventures to raise up to $500m in new funding.

E-cigarette brand Juul disclosed $325m of convertible debt financing last month, and a subsequent securities filing has indicated the size of the round is now $785m. It’s currently unclear who the 14 investors are that supplied the capital but they may well include Altria, the tobacco provider that invested a whopping $12.8bn late last year in order to buy more than a third of the company.

Hydrogen electric truck developer Nikola Corporation has raised $250m in cash and services from industrial equipment producer and strategic investor CNH Industrial for a series D round it aims to close at $1bn or more. The round values Nikola at $3bn pre-money, and while there’s no word of additional investors yet, its existing backers include fellow corporates Nel Hydrogen and Wabco.

With all the fuss surrounding Uber and its peers, it can be easy to forget that before ride hailing was ‘a thing’, car sharing was viewed as the future of transport. Getaround is still ploughing that furrow and is pulling in funding, aiming to add $200m in capital to the $300m it raised last year.

Tencent has provided $120m in series E funding for customer relationship management (CRM) software provider Xiaoshouyi. The company, which is also known as IngageApp, had already secured more than $40m in a Tencent-led series D round in 2017 before reportedly adding nearly $16m from the same investor the following year. It has also worked in tandem with Tencent on a specialist CRM product.

Nkarta Therapeutics has emerged from stealth with $114m raised in a series B round featuring Amgen Ventures and existing investors Novo and SR One. The company, which has received $129m in total, is developing treatments for cancer that rely on sparking the body’s natural killer cells to kill cancerous cells.

Passage Bio packs in another $110m

Yongcheng Life has secured $100m in a series B round led by Legend Capital that included Bertelsmann Asia Investments (BAI).

University

Ginger jumps to $35m series C

Achilles Therapeutics accesses $120m

Exits

Vertex Pharmaceuticals has agreed to buy diabetes treatment developer Semma Therapeutics in a $950m all-cash deal that will enable Medtronic, Novartis and SinoPharm to exit.

Data management software provider Commvaultis set to pay $225m to acquire Hedvig, a software-defined storage technology producer backed by Hewlett Packard Enterprise.

Kabbage pinpoints Radius for acquisition

Viela Bio has filed for a $150m initial public offering less than two years after being spun off by AstraZeneca. The corporate is still the largest shareholder in autoimmune disease drug developer Viela, having invested $142m last year, and it holds a stake sized above 38%.

Vir veers toward public markets

Investors in cloud security software provider Druva may be heading toward a different kind of exit, as news emerges that the company plans to begin prepping an initial public offering over the course of this year.

Uhuru to pursue $50m in London IPO

Funds

Taiwan Life ties $50m to BVP Century Fund

DG Daiwa Ventures, the joint investment venture set up by internet company Digital Garage and brokerage Daiwa Securities, has formed a new fund called DG Lab Fund II that is seeking a close of about $188m.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0